^
Association details:
| Biomarker: | CD8 underexpression + HAVCR2 overexpression |
|---|---|
| Cancer: | Melanoma |
| Drug Class: | CTLA4 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Blood T-cell profiling in metastatic melanoma patients as a marker for response to immune checkpoint inhibitors combined with radiotherapy
Published date:
06/27/2022
Excerpt:
24 poly-metastatic melanoma patients participated in the SABR IMPACT trial, receiving standard dose immunotherapy with anti-PD-1 and/or anti-CTLA-4 and stereotactic ablative radiotherapy to one site….A multivariate discriminant analysis revealed a baseline signature of lower levels of CD8+ naive T-cells and higher expression of TIM-3 on regulatory T-cells and memory T-cells better predicted response.
DOI:
10.1016/j.radonc.2022.06.016
